Nov 04, 2025 • Benzinga
NEUTRAL
Repligen Corporation to Present at Upcoming November Conferences - Repligen ( NASDAQ:RGEN )
WALTHAM, Mass., Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- Repligen Corporation ( NASDAQ:RGEN ) , a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending five upcoming investor conferences.
Oct 29, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down
Repligen posts strong Q3 results with revenue growth and an earnings beat, yet shares dip as tighter EPS guidance tempers investor optimism.
Oct 28, 2025 • Zacks Commentary
NEUTRAL
Repligen ( RGEN ) Q3 Earnings and Revenues Surpass Estimates
Repligen (RGEN) delivered earnings and revenue surprises of +9.52% and +4.18%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Oct 23, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Apellis Pharmaceuticals, Inc. ( APLS ) Reports Next Week: Wall Street Expects Earnings Growth
Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oct 21, 2025 • Zacks Commentary
BULLISH
ALKS vs. RGEN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Alkermes ( ALKS Quick QuoteALKS - ) or Repligen ( RGEN Quick QuoteRGEN - ) . But which of these two stocks offers value investors a better bang for their buck right now?
Oct 21, 2025 • Zacks Commentary
NEUTRAL
Earnings Preview: Repligen ( RGEN ) Q3 Earnings Expected to Decline
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.